American Journal of Cardiology
Volume 103, Issue 2 , Pages 273-278 , 15 January 2009

Comparison of Nebivolol Monotherapy Versus Nebivolol in Combination With Other Antihypertensive Therapies for the Treatment of Hypertension

Received 13 July 2008 ,Revised 22 August 2008 ,Accepted 22 August 2008.

References 

  1. Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92:344–348
  2. Czuriga I, Riecansky I, Bodnar J, Fulop T, Kruzsicz V, Kristof E, et al. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther. 2003;17:257–263
  3. Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B, Mancia G. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press Suppl. 2003;2:35–40
  4. Van Nueten L, Lacourciere Y, Vyssoulis G, Korlipara K, Marcadet DM, Dupont AG, et al. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial. Am J Ther. 1998;5:237–243
  5. Van Nueten L, Schelling A, Vertommen C, Dupont AG, Robertson JI. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial. J Hum Hypertens. 1997;11:813–819
  6. Van Nueten L, Taylor FR, Robertson JI. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens. 1998;12:135–140
  7. Cleophas TJ, Grabowsky I, Niemeyer MG, Makel WN, van der Wall EE. Long-term efficacy of nebivolol monotherapy in patients with hypertension. Curr Ther Res Clin Exp. 2001;62:451–461
  8. Greathouse M. A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to assess the efficacy and safety of nebivolol in patients with stage I or II hypertension. Clin Cardiol. 2008;In press
  9. Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich). 2007;9:866–875
  10. Weiss RJ, Weber MA, Carr AA, Sullivan WA. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich). 2007;9:667–676
  11. Ambrosioni E, Borghi C. Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective beta-blockers in the treatment of hypertension: a meta-analysis. High Blood Press Cardiovasc Prev. 2005;12:27–35
  12. Gradman A. Safety and tolerability of nebivolol: a pooled safety analysis comparing typical β-blocker–associated adverse events with placebo. J Clin Hypertens (Greenwich). 2008;10(suppl A):A120
  13. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572
  14. Bristow MR, Nelson P, Minobe W, Johnson C. Characterization of β1-adrenergic receptor selectivity of nebivolol and various other beta-blockers in human myocardium. Am J Hypertens. 2005;18(suppl):51A–52A
  15. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CPL-H, Dupont AG, van Nueten L, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995;274:1067–1071
  16. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind crossover study. Circulation. 2001;104:511–514
  17. Prichard BN, Cruickshank JM, Graham BR. Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Press. 2001;10:366–386
  18. Wojciechowski B, Papademetriou V. β-Blockers in the management of hypertension: focus on nebivolol. Expert Cardiovasc Ther. 2008;6:471–479
  19. Gupta S, Wright H. Nebivolol: a highly selective β1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Cardiovasc Ther. 2008;In press
  20. Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006;99:431–436
  21. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227–2236
  22. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non–insulin-dependent diabetes mellitus and hypertension (A randomized, controlled trial). Ann Intern Med. 1997;126:955–959
  23. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol–metoprolol study. J Hypertens. 1996;14:489–494
  24. Poirier L, Cleroux J, Nadeau A, Lacourciere Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens. 2001;19:1429–1435
  25. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the diagnosis and treatment of hypertension. Endocr Pract. 2006;12:193–222
  26. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462–1536
  27. Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al Glucose intolerance during diuretic therapy in elderly hypertensive patients (A second report from the European Working Party on high blood pressure in the elderly (EWPHE)). Postgrad Med J. 1986;62:919–924
  28. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006;166:2191–2201
  29. Grassi G, Seravalle G, Dell'Oro R, Trevano FQ, Bombelli M, Scopelliti F, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens. 2003;21:1761–1769

PII: S0002-9149(08)01582-8

doi: 10.1016/j.amjcard.2008.08.063

American Journal of Cardiology
Volume 103, Issue 2 , Pages 273-278 , 15 January 2009

Article Tools

* Image Usage & Resolution